Nga T Dai
Overview
Explore the profile of Nga T Dai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel A, Flatten K, Schneider P, Dai N, McDonald J, Poirier G, et al.
J Biol Chem
. 2011 Dec;
287(6):4198-210.
PMID: 22158865
Poly(ADP-ribose) polymerase-1 (PARP1) plays critical roles in the regulation of DNA repair. Accordingly, small molecule inhibitors of PARP are being developed as agents that could modulate the activity of genotoxic...
2.
Karp J, Flatten K, Feldman E, Greer J, Loegering D, Ricklis R, et al.
Blood
. 2008 Dec;
113(20):4841-52.
PMID: 19109557
The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream...
3.
Galvez-Peralta M, Dai N, Loegering D, Flatten K, Safgren S, Wagner J, et al.
Mol Pharmacol
. 2008 May;
74(3):724-35.
PMID: 18509065
Although agents that inhibit DNA synthesis are widely used in the treatment of cancer, the optimal method for combining such agents and the mechanism of their synergy is poorly understood....
4.
Hackbarth J, Galvez-Peralta M, Dai N, Loegering D, Peterson K, Meng X, et al.
J Biol Chem
. 2008 Apr;
283(24):16711-22.
PMID: 18408216
Human DNA topoisomerase I (topo I) is an essential mammalian enzyme that regulates DNA supercoiling during transcription and replication. In addition, topo I is specifically targeted by the anticancer compound...
5.
Meng X, Lee S, Dai H, Loegering D, Yu C, Flatten K, et al.
J Biol Chem
. 2007 Aug;
282(41):29831-46.
PMID: 17698840
Previous studies have suggested that Mcl-1, an antiapoptotic Bcl-2 homolog that does not exhibit appreciable affinity for the caspase 8-generated C-terminal Bid fragment (tBid), diminishes sensitivity to tumor necrosis factor-alpha-related...
6.
Mesa R, Loegering D, Powell H, Flatten K, Arlander S, Dai N, et al.
Blood
. 2005 Mar;
106(1):318-27.
PMID: 15784732
Previous studies demonstrated that ataxia telangiectasia mutated- and Rad3-related (ATR) kinase and its downstream target checkpoint kinase 1 (Chk1) facilitate survival of cells treated with nucleoside analogs and other replication...
7.
Flatten K, Dai N, Vroman B, Loegering D, Erlichman C, Karnitz L, et al.
J Biol Chem
. 2005 Feb;
280(14):14349-55.
PMID: 15699047
Agents that target topoisomerase I are widely utilized to treat human cancer. Previous studies have indicated that both the ataxia telangiectasia mutated (ATM)/checkpoint kinase (Chk) 2 and ATM- and Rad...
8.
Ghobrial I, McCormick D, Kaufmann S, Leontovich A, Loegering D, Dai N, et al.
Blood
. 2005 Jan;
105(9):3722-30.
PMID: 15650054
Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies,...